ReviewCancers2022
Magnetic Resonance Imaging-Based Radiomics for the Prediction of Progression-Free Survival in Patients with Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive performance of MRI and CT radiomics in predicting the response to induction chemotherapy in nasopharyngeal carcinoma: a network meta-analysis.Frontiers in oncology · 2025Pooled it
- Prognostic value of the three-lineage cytopenia score in locally advanced nasopharyngeal carcinoma: A retrospective cohort study.PloS one · 2026Article
- Integrated clinical-radiomic model for predicting treatment response of concurrent chemo-radiotherapy and radiotherapy alone in controversial subgroup of AJCC/UICC ninth edition stage I nasopharyngeal cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Article
- Integrative radiopathomics model for predicting progression-free survival in patients with nonmetastatic nasopharyngeal carcinoma.Journal of cancer research and clinical oncology · 2024Article
- Deciphering the Prognostic Efficacy of MRI Radiomics in Nasopharyngeal Carcinoma: A Comprehensive Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Article
- Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clinical and Blood Laboratory Parameters.OncoTargets and therapy · 2024Article
- Radiomics for predicting survival in patients with locally advanced rectal cancer: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- An overview of meta-analyses on radiomics: more evidence is needed to support clinical translation.Insights into imaging · 2023Article
- Survival rate prediction of nasopharyngeal carcinoma patients based on MRI and gene expression using a deep neural network.Cancer science · 2023Article
- Automatic tumor segmentation and metachronous single-organ metastasis prediction of nasopharyngeal carcinoma patients based on multi-sequence magnetic resonance imaging.Frontiers in oncology · 2023Article
- Frontiers and hotspots ofFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Advanced non-metastatic nasopharyngeal carcinoma (NPC) has variable treatment outcomes. However, there are no prognostic biomarkers for identifying high-risk patients with NPC. The aim of this systematic review and meta-analysis was to comprehensively assess the prognostic value of magnetic resonance imaging (MRI)-based radiomics for untreated NPC. The PubMed-Medline and EMBASE databases were searched for relevant articles published up to 12 August 2021. The Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) checklist was used to determine the qualities of the selected studies. Random-effects modeling was used to calculate the pooled estimates of Harrell's concordance index (C-index) for progression-free survival (PFS). Between-study heterogeneity was evaluated using Higgins' inconsistency index (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.